R.R. Baliga/LinkedIn
Jul 1, 2026, 08:48
R.R. Baliga: The New JACC/ACC 2026 Statement Reinforces That DOAC Therapy Is Never One Size Fits All
R.R. Baliga, Editor-In-Chief of Textbook of Internal Medicine: Helping You Become a Great Doc, shared on LinkedIn:
”New JACC/ACC 2026 Scientific Statement spotlight: DOACs are now central to stroke and venous thromboembolism prevention—but not ‘one size fits all.’
The practical message: choose the right agent, dose correctly, avoid DOACs in mechanical valves and rheumatic mitral stenosis, reassess renal/liver function, bleeding risk, drug interactions, adherence, and cost.
In anticoagulation, the prescription is only the opening move; follow-up is where safety lives.”
Stay updated with Hemostasis Today.
-
Oct 2, 2026, 13:50Arnav Garcha: New Insights Into Platelet Transport in Arterial Flow
-
Oct 2, 2026, 13:49Alessandro Lucchesi: RiseMPN 2026 – Shaping the Future of MPN Treatment
-
Oct 2, 2026, 13:43Ronald Mahomane: Bangladesh Moves Toward Sustainable Hemophilia Treatment Access
-
Oct 2, 2026, 13:38Sathya-Prasad Burjonrappa: Pediatric Trauma and Deep Venous Thrombosis
-
Oct 2, 2026, 12:50Ravi C Dara: ADHAR 2026 – Red Cell Exchange in Sickle Cell Disease
-
Oct 2, 2026, 12:37David McIntosh: WeDonate Partners with Dr. Martens to Reward UK Blood Donors
-
Oct 2, 2026, 12:31Ahmed Salah El-Deen: HELLP Syndrome – An Obstetric Emergency
-
Oct 2, 2026, 12:28Swapnil Hiremath: Transitioning from Idiopathic Thrombocytopenia to Antiphospholipid Syndrome in Recurrent Severe Preeclampsia
-
Oct 2, 2026, 12:08Austin Camp: Learn How to Treat HIT from an ICU Pharmacist in 60 Seconds!